Skip to main content
Top
Published in: Infection 1/2014

01-02-2014 | Case Report

Spontaneous bacterial peritonitis by Pasteurella multocida under treatment with rifaximin

Authors: P. Lutz, M. Parcina, I. Bekeredjian-Ding, A. Hoerauf, C. P. Strassburg, U. Spengler

Published in: Infection | Issue 1/2014

Login to get access

Abstract

Spontaneous bacterial peritonitis (SBP) is a life-threatening complication of liver cirrhosis. Recently, rifaximin, a non-absorbable antibiotic which is used to prevent recurrent hepatic encephalopathy, has been proposed as effective prophylaxis for SBP. Here, we present an unusual case of SBP under treatment with rifaximin. A 50-year-old woman with liver cirrhosis was admitted because of tense ascites and abdominal pain. She was under long-term oral prophylaxis with rifaximin due to hepatic encephalopathy. Paracentesis revealed SBP caused by Pasteurella multocida, which was sensitive to multiple antibiotics, including rifaximin. Treatment with ceftriaxone resulted in rapid resolution of the peritonitis and restoration of the patient. Since P. multocida is usually transmitted from pets, the patient’s cat was tested and could be identified as the most likely source of infection. This case should elicit our awareness that uncommon pathogens and unusual routes of transmission may lead to SBP, despite antibacterial prophylaxis with non-absorbable antibiotics. Nevertheless, such infections may still remain sensitive to systemic therapy with conventional antibiotics.
Literature
1.
go back to reference Scarpignato C, Pelosini I. Experimental and clinical pharmacology of rifaximin, a gastrointestinal selective antibiotic. Digestion 2006;73:13–27.PubMedCrossRef Scarpignato C, Pelosini I. Experimental and clinical pharmacology of rifaximin, a gastrointestinal selective antibiotic. Digestion 2006;73:13–27.PubMedCrossRef
2.
go back to reference Hu Y, Ren J, Zhan M, Li W, Dai H. Efficacy of rifaximin in prevention of travelers’ diarrhea: a meta-analysis of randomized, double-blind, placebo-controlled trials. J Travel Med. 2012;19:352–6.PubMedCrossRef Hu Y, Ren J, Zhan M, Li W, Dai H. Efficacy of rifaximin in prevention of travelers’ diarrhea: a meta-analysis of randomized, double-blind, placebo-controlled trials. J Travel Med. 2012;19:352–6.PubMedCrossRef
3.
go back to reference Yun SP, Seon HG, Ok CS, Yoo KH, Kang MK, Kim WH, Kwon CI, Ko KH, Hwang SG, Park PW, Hong SP. Rifaximin plus levofloxacin-based rescue regimen for the eradication of Helicobacter pylori. Gut Liver. 2012;6:452–6.PubMedCentralPubMedCrossRef Yun SP, Seon HG, Ok CS, Yoo KH, Kang MK, Kim WH, Kwon CI, Ko KH, Hwang SG, Park PW, Hong SP. Rifaximin plus levofloxacin-based rescue regimen for the eradication of Helicobacter pylori. Gut Liver. 2012;6:452–6.PubMedCentralPubMedCrossRef
4.
go back to reference Mattila E, Arkkila P, Mattila PS, Tarkka E, Tissari P, Anttila VJ. Rifaximin in the treatment of recurrent Clostridium difficile infection. Aliment Pharmacol Ther. 2013;37:122–8.PubMedCrossRef Mattila E, Arkkila P, Mattila PS, Tarkka E, Tissari P, Anttila VJ. Rifaximin in the treatment of recurrent Clostridium difficile infection. Aliment Pharmacol Ther. 2013;37:122–8.PubMedCrossRef
5.
go back to reference Hanouneh MA, Hanouneh IA, Hashash JG, Law R, Esfeh JM, Lopez R, Hazratjee N, Smith T, Zein NN. The role of rifaximin in the primary prophylaxis of spontaneous bacterial peritonitis in patients with liver cirrhosis. J Clin Gastroenterol. 2012;46:709–15.PubMedCrossRef Hanouneh MA, Hanouneh IA, Hashash JG, Law R, Esfeh JM, Lopez R, Hazratjee N, Smith T, Zein NN. The role of rifaximin in the primary prophylaxis of spontaneous bacterial peritonitis in patients with liver cirrhosis. J Clin Gastroenterol. 2012;46:709–15.PubMedCrossRef
6.
go back to reference Vlachogiannakos J, Viazis N, Vasianopoulou P, Vafiadis I, Karamanolis DG, Ladas SD. Long-term administration of rifaximin improves the prognosis of patients with decompensated alcoholic cirrhosis. J Gastroenterol Hepatol. 2013;28:450–5.PubMedCrossRef Vlachogiannakos J, Viazis N, Vasianopoulou P, Vafiadis I, Karamanolis DG, Ladas SD. Long-term administration of rifaximin improves the prognosis of patients with decompensated alcoholic cirrhosis. J Gastroenterol Hepatol. 2013;28:450–5.PubMedCrossRef
7.
go back to reference Wiest R, Krag A, Gerbes A. Spontaneous bacterial peritonitis: recent guidelines and beyond. Gut 2012;61:297–310.PubMedCrossRef Wiest R, Krag A, Gerbes A. Spontaneous bacterial peritonitis: recent guidelines and beyond. Gut 2012;61:297–310.PubMedCrossRef
8.
go back to reference Bass NM, Mullen KD, Sanyal A, Poordad F, Neff G, Leevy CB, Sigal S, Sheikh MY, Beavers K, Frederick T, Teperman L, Hillebrand D, Huang S, Merchant K, Shaw A, Bortey E, Forbes WP. Rifaximin treatment in hepatic encephalopathy. N Engl J Med. 2010;362:1071–81.PubMedCrossRef Bass NM, Mullen KD, Sanyal A, Poordad F, Neff G, Leevy CB, Sigal S, Sheikh MY, Beavers K, Frederick T, Teperman L, Hillebrand D, Huang S, Merchant K, Shaw A, Bortey E, Forbes WP. Rifaximin treatment in hepatic encephalopathy. N Engl J Med. 2010;362:1071–81.PubMedCrossRef
9.
go back to reference Eltawil KM, Laryea M, Peltekian K, Molinari M. Rifaximin vs. conventional oral therapy for hepatic encephalopathy: a meta-analysis. World J Gastroenterol. 2012;18:767–77.PubMedCrossRef Eltawil KM, Laryea M, Peltekian K, Molinari M. Rifaximin vs. conventional oral therapy for hepatic encephalopathy: a meta-analysis. World J Gastroenterol. 2012;18:767–77.PubMedCrossRef
10.
go back to reference European Association for the Study of the Liver. EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J Hepatol. 2010;53:397–417.CrossRef European Association for the Study of the Liver. EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J Hepatol. 2010;53:397–417.CrossRef
11.
go back to reference Hubbert WT, Rosen MN. Pasteurella multocida infections. II. Pasteurella multocida infection in man unrelated to animal bite. Am J Public Health Nations Health. 1970;60:1109–17.PubMedCentralPubMedCrossRef Hubbert WT, Rosen MN. Pasteurella multocida infections. II. Pasteurella multocida infection in man unrelated to animal bite. Am J Public Health Nations Health. 1970;60:1109–17.PubMedCentralPubMedCrossRef
12.
go back to reference Fernández J, Acevedo J, Castro M, Garcia O, de Lope CR, Roca D, Pavesi M, Sola E, Moreira L, Silva A, Seva-Pereira T, Corradi F, Mensa J, Ginès P, Arroyo V. Prevalence and risk factors of infections by multiresistant bacteria in cirrhosis: a prospective study. Hepatology 2012;55:1551–61.PubMedCrossRef Fernández J, Acevedo J, Castro M, Garcia O, de Lope CR, Roca D, Pavesi M, Sola E, Moreira L, Silva A, Seva-Pereira T, Corradi F, Mensa J, Ginès P, Arroyo V. Prevalence and risk factors of infections by multiresistant bacteria in cirrhosis: a prospective study. Hepatology 2012;55:1551–61.PubMedCrossRef
13.
go back to reference Reuken PA, Pletz MW, Baier M, Pfister W, Stallmach A, Bruns T. Emergence of spontaneous bacterial peritonitis due to enterococci—risk factors and outcome in a 12-year retrospective study. Aliment Pharmacol Ther. 2012;35:1199–208.PubMedCrossRef Reuken PA, Pletz MW, Baier M, Pfister W, Stallmach A, Bruns T. Emergence of spontaneous bacterial peritonitis due to enterococci—risk factors and outcome in a 12-year retrospective study. Aliment Pharmacol Ther. 2012;35:1199–208.PubMedCrossRef
14.
go back to reference Tamaskar I, Ravakhah K. Spontaneous bacterial peritonitis with Pasteurella multocida in cirrhosis: case report and review of literature. South Med J. 2004;97:1113–5.PubMedCrossRef Tamaskar I, Ravakhah K. Spontaneous bacterial peritonitis with Pasteurella multocida in cirrhosis: case report and review of literature. South Med J. 2004;97:1113–5.PubMedCrossRef
15.
go back to reference Sol PM, van de Kar NC, Schreuder MF. Cat induced Pasteurella multocida peritonitis in peritoneal dialysis: a case report and review of the literature. Int J Hyg Environ Health. 2013;216:211–3.PubMedCrossRef Sol PM, van de Kar NC, Schreuder MF. Cat induced Pasteurella multocida peritonitis in peritoneal dialysis: a case report and review of the literature. Int J Hyg Environ Health. 2013;216:211–3.PubMedCrossRef
16.
go back to reference Miller MA, Blanchette R, Spigaglia P, Barbanti F, Mastrantonio P. Divergent rifamycin susceptibilities of Clostridium difficile strains in Canada and Italy and predictive accuracy of rifampin Etest for rifamycin resistance. J Clin Microbiol. 2011;49:4319–21.PubMedCentralPubMedCrossRef Miller MA, Blanchette R, Spigaglia P, Barbanti F, Mastrantonio P. Divergent rifamycin susceptibilities of Clostridium difficile strains in Canada and Italy and predictive accuracy of rifampin Etest for rifamycin resistance. J Clin Microbiol. 2011;49:4319–21.PubMedCentralPubMedCrossRef
17.
go back to reference Kothary V, Scherl EJ, Bosworth B, Jiang ZD, Dupont HL, Harel J, Simpson KW, Dogan B. Rifaximin resistance in Escherichia coli associated with inflammatory bowel disease correlates with prior rifaximin use, mutations in rpoB, and activity of Phe-Arg-β-naphthylamide-inhibitable efflux pumps. Antimicrob Agents Chemother. 2013;57:811–7.PubMedCentralPubMedCrossRef Kothary V, Scherl EJ, Bosworth B, Jiang ZD, Dupont HL, Harel J, Simpson KW, Dogan B. Rifaximin resistance in Escherichia coli associated with inflammatory bowel disease correlates with prior rifaximin use, mutations in rpoB, and activity of Phe-Arg-β-naphthylamide-inhibitable efflux pumps. Antimicrob Agents Chemother. 2013;57:811–7.PubMedCentralPubMedCrossRef
18.
go back to reference Valentin T, Leitner E, Rohn A, Zollner-Schwetz I, Hoenigl M, Salzer HJ, Krause R. Rifaximin intake leads to emergence of rifampin-resistant staphylococci. J Infect. 2011;62:34–8.PubMedCrossRef Valentin T, Leitner E, Rohn A, Zollner-Schwetz I, Hoenigl M, Salzer HJ, Krause R. Rifaximin intake leads to emergence of rifampin-resistant staphylococci. J Infect. 2011;62:34–8.PubMedCrossRef
19.
go back to reference Avril JL, Donnio PY, Pouedras P. Selective medium for Pasteurella multocida and its use to detect oropharyngeal carriage in pig breeders. J Clin Microbiol. 1990;28:1438–40.PubMedCentralPubMed Avril JL, Donnio PY, Pouedras P. Selective medium for Pasteurella multocida and its use to detect oropharyngeal carriage in pig breeders. J Clin Microbiol. 1990;28:1438–40.PubMedCentralPubMed
20.
go back to reference Siahanidou T, Gika G, Skiathitou AV, Oikonomopoulos T, Alexandrou-Athanassoulis H, Koutouzis EI, Syriopoulou VP. Pasteurella multocida infection in a neonate: evidence for a human-to-human horizontal transmission. Pediatr Infect Dis J. 2012;31:536–7.PubMedCrossRef Siahanidou T, Gika G, Skiathitou AV, Oikonomopoulos T, Alexandrou-Athanassoulis H, Koutouzis EI, Syriopoulou VP. Pasteurella multocida infection in a neonate: evidence for a human-to-human horizontal transmission. Pediatr Infect Dis J. 2012;31:536–7.PubMedCrossRef
Metadata
Title
Spontaneous bacterial peritonitis by Pasteurella multocida under treatment with rifaximin
Authors
P. Lutz
M. Parcina
I. Bekeredjian-Ding
A. Hoerauf
C. P. Strassburg
U. Spengler
Publication date
01-02-2014
Publisher
Springer Berlin Heidelberg
Published in
Infection / Issue 1/2014
Print ISSN: 0300-8126
Electronic ISSN: 1439-0973
DOI
https://doi.org/10.1007/s15010-013-0449-4

Other articles of this Issue 1/2014

Infection 1/2014 Go to the issue

Clinical and Epidemiological Study

Fulminant hepatitis due to human adenovirus

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.